Changing Your Patients' Lives 90 Days at a Time

The 90-day fluorescent sensor is inserted just under the skin of your patient's upper arm and continuously measures glucose for up to 3 months. We also provide you training on the simple, in-office insertion and removal procedures.

Sensor Image
 

Actual Size:
3.5 MM x 18.3 MM

 
 

90-Day Sensor

Provides freedom from frequent self-insertions

4 Sensor changes/year

vs. 26-52 for other CGM Systems

Minimized maintenance

and management of supplies

Reduced number of

day-1 warm-up periods

 

Due to its subcutaneous insertion, Eversense helps patients increase wear time to an average of 98%3, which exceeds the 80% threshold for optimal clinical benefit.1

Having the sensor inserted is straightforward and safe.

Unlike traditional blood glucose sensors, the Eversense CGM Sensor is inserted subcutaneously in the upper arm by a trained health care provider. No part of the sensor shows through the skin surface.

Your nurse practicioner or physician’s assistant can also be trained to insert the sensor, making this advanced technology available to more patients.

92% of patients reported no pain and discomfort when using the Sensor(1)
 

The sensor placement went very well. I felt nothing, no pain, no discomfort. There are no stitches, no sutures, just two steri strips and a bandage.

Robert, Eversense CGM User

See why Robert loves Eversense*

More about the sensor technology and how it works.

The Eversense sensor is made of a biocompatible material and it utilizes a patented fluorescent, glucose-indicating polymer technology to measure glucose in the interstitial fluid. The measurement is then relayed to the smart transmitter. The measurement and display of glucose values is done automatically, without the need for user intervention.

Sensor Video Thumbnail

Features & Function

Icon Dots

Advanced fluorescence technology

Icon Calendar

Sensor lasts up to 90 days - eliminates frequent self-insertions

Icon On-Body

Only CGM providing on-body vibe alerts when glucose is low or high

Icon Accuracy

Very accurate over a 90-day period with MARD of 8.5%3

no-fingersticks

No fingersticks for treatment decisions




  1. Sanchez P, Ghosh-Dastidar S, Tweden K, Kaufman F. Real-World Data from the First US Commercial Users of an Implantable Continuous Glucose Sensor. Diabetes Technol Ther. Published online August 12, 2019, DOI:10.1089/dia.2019.0234.
  2. Barnard KD, Kropff J, et al. Acceptability of Implantable Continuous Glucose Monitoring Sensor: Journal of Diabetes Science and Technology 2018, Vol. 12(3) 634 -638. DOI: 10.1177.
  3. Christiansen MP, Klaff LJ, Brazg R, et al. A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. Diabetes Technology & Therapeutics. 2018; 20(3): 197 -206